Improving combination therapies: Targeting A2B adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression

Autor: Jason V Evans, Shankar Suman, Mounika Uttam L Goruganthu, Elena E Tchekneva, Shuxiao Guan, Rajeswara Rao Arasada, Anneliese Antonucci, Longzhu Piao, Irina Ilgisonis, Andrey A Bobko, Benoit Driesschaert, Roman V Uzhachenko, Rebecca Hoyd, Alexandre Samouilov, Joseph Amann, Ruohan Wu, Lai Wei, Aaditya Pallerla, Sergey V Ryzhov, Igor Feoktistov, Kyungho P Park, Takefumi Kikuchi, Julio Castro, Alla V Ivanova, Thanigaivelan Kanagasabai, Dwight H Owen, Daniel J Spakowicz, Jay L Zweier, David P Carbone, Sergey V Novitskiy, Valery V Khramtsov, Anil Shanker, Mikhail M Dikov
Rok vydání: 2023
Předmět:
Zdroj: JNCI: Journal of the National Cancer Institute.
ISSN: 1460-2105
0027-8874
DOI: 10.1093/jnci/djad091
Popis: Background We investigated the role of A2B-adenosine receptor (A2BAR) in regulating immunosuppressive metabolic stress in the tumor microenvironment (TME). Novel A2BAR antagonist PBF-1129 was tested for anti-tumor activity in animals and evaluated for safety and immunological efficacy in a phase-I clinical trial in non-small-cell lung cancer (NSCLC) patients. Methods Anti-tumor efficacy of A2BAR antagonists and impact on metabolic and immune TME was evaluated in lung, melanoma, colon, breast and EGFR-inducible transgenic cancer models. Employing Electron Paramagnetic Resonance, we assessed changes in TME metabolic parameters including pO2, pH, and inorganic phosphate (Pi) during tumor growth and evaluated the immunological effects of PBF-1129, including its pharmacokinetics, safety, and toxicity in NSCLC patients. Results Levels of metabolic stress correlated with tumor growth, metastasis, and immunosuppression. Tumor interstitial Pi emerged as a correlative and cumulative measure of TME stress and immunosuppression. A2BAR inhibition alleviated metabolic stress, downregulated expression of adenosine-generating ecto-nucleotidases, increased expression of adenosine deaminase (ADA), decreased tumor growth and metastasis, increased IFN-γ-production and enhanced the efficacy of anti-tumor therapies following combination regimens in animal models (anti-PD-1 vs. anti-PD-1 plus PBF-1129 treatment hazard ratio [HR] = 11.74, 95% CI = 3.35 to 41.13, n = 10, P Conclusions Data identify A2BAR as a valuable therapeutic target to modify metabolic and immune TME to reduce immunosuppression, enhance the efficacy of immunotherapies, and support clinical application of PBF-1129 in combination therapies.
Databáze: OpenAIRE
Externí odkaz: